[Ip-health] The NIH

George Carter gmcfiar at gmail.com
Tue Jun 21 09:36:17 PDT 2016

> On Jun 21, 2016, at 11:21 AM, Paul Davis <pdavisx at gmail.com> wrote:
> The next POTUS needs to 1) appoint a new director, and 2) issue clear instructions correcting these violations of public interest and neglect of responsibility. 
> NIH is not fulfilling it’s function is to advance health science for public good. It is instead operating as corporate welfare for big pharma. 

Nonsense, Paul! Of course it cares about the public good. 
If you narrowly define “public” as pharma CEOs who brazenly fiscally rape public (and private) funds to enrich themselves lavishly, no matter how many are harmed or die. You know like Milligan, Martin, Alton and the other executive class slime at Gilead, as but one example.

The only way we’ll break them is to start getting more people on things like Darvoni, actually a better combo of sofosbuvir and daclatasvir (pangenotypic) at around $400 (I think?) for a 12-week course. Getting lots of people hooked up that way.

We just have to start getting the generics in. Co-pays are almost as much most of the time, anyway. They’ve crafted law and perverted public institutions long enough in the service of these genoicdal profiteers. Time to bypass them entirely and get patients the help they need, the world over.
George M. Carter

> We need to make sure the 2016 candidates know that we reject this (ab)use of basic fairness and ROI for taxpayer resources.
>> Paul Davis
> +1 202 817 0129
> Skype/im: pdavisx
>> On Jun 21, 2016, at 11:01 AM, Jamie Love <james.love at keionline.org> wrote:
>> I'm not sure how aware people are of the increasingly anti-taxpayer and
>> anti-public positions that the NIH is taking on intellectual property
>> property rights on publicly funded R&D.  The very short and blunt rejection
>> of the Xtandi petition, on the basis that the drug is for sale in United
>> States, and that's all the Bayh-Dole Act requires, is just one of several
>> appalling data points. The NIH is refusing to provide even basic
>> information about the licenses it offers on government funded inventions,
>> abusing the start-up licensing program, companies now advertise their
>> connections to NIH personnel for licencing as a company asset, the NIH
>> won't disclose any useful information about the licenses it does issue, and
>> it routinely ignores 35 USC 209 requirements to limit the uses and scope of
>> rights in exclusive licenses.
>> More on this in several places including:
>> http://keionline.org/nih-licenses
>> http://keionline.org/xtandi
>> http://keionline.org/government-funded-inventions
>> ​Next week we will host a conference call or a webstreamed meeting to
>> discuss these issues in more detail.
>> -- 
>> James Love.  Knowledge Ecology International
>> http://www.keionline.org/donate.html
>> KEI DC tel: +1.202.332.2670, US Mobile: +1.202.361.3040, Geneva Mobile:
>> +41.76.413.6584, twitter.com/jamie_love
>> _______________________________________________
>> Ip-health mailing list
>> Ip-health at lists.keionline.org
>> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org

More information about the Ip-health mailing list